Perfuze Presents Preliminary Results from MARRS Pivotal Trial at SNIS, Highlighting Millipede 88 Performance in Acute Ischemic Stroke
'The MARRS data are truly exceptional. Achieving 77% First Pass Effect for M1 occlusions in a pivotal study is a major advance for stroke care," said Dr. Raul G. Nogueira, Principal Investigator of the MARRS Study.
Share
The trial is evaluating the safety and effectiveness of the Millipede System for revascularization in acute ischemic stroke. Conducted across a network of leading stroke centers in the U.S. and Europe, the study included patients with occlusions in the ICA, M1, M2 and basilar, or vertebral arteries. The Millipede System includes the Millipede 88 aspiration catheter, Perfuze's flagship Superbore aspiration catheter.
The MARRS trial enrolled 180 evaluable subjects, with first pass direct aspiration being performed with the Millipede 88 in 101 of these patients. The preliminary analysis shows a high rate of First Pass Effect (FPE), defined as complete or near-complete revascularization (mTICI 2c) following a single device pass. For patients treated with Millipede 88, an FPE rate of 61% was observed across all target vessels in the Per Protocol (PP) population. Specifically, for M1 artery occlusions treated with Millipede 88 in the PP population, an FPE rate of 77% was achieved.
'The MARRS data are truly exceptional. Achieving 77% First Pass Effect for M1 occlusions in a pivotal study is a major advance for stroke care. The ability to reliably achieve rapid, complete reperfusion with a single aspiration pass is exactly what we need to improve efficacy. This technology is a powerful tool that simplifies thrombectomy and delivers outstanding performance,' said Dr. Raul G. Nogueira, Principal Investigator of the MARRS Study and Professor of Neurology and Neurosurgery at the University of Pittsburgh School of Medicine.
Across the 180 patients enrolled, delivery success of the Millipede System was 99%, and the median number of passes was 1. Preliminary safety analysis showed a symptomatic intracranial hemorrhage (sICH) rate of 1.7%. Perforation was reported at 0% and the rate of intracranial dissection was 1.1%, indicating a promising safety profile.
' The MARRS study represents several years of work by the Perfuze team and our clinical partners,' said Wayne Allen, CEO and Co-Founder of Perfuze. ' We designed the Millipede 88 to navigate seamlessly to the clot face, enabling a superbore catheter that improves the likelihood of achieving First Pass Effect. This early data reflects that intent, and we're encouraged by the physician feedback we've received to date.'
The MARRS trial completed enrollment earlier this year, executed ahead of schedule, reflecting strong engagement from stroke centers and interest in next-generation aspiration technology. These clinical results follow several successful milestones for Perfuze, including FDA 510(k) clearance for its Zipline™ Access Catheters and a €22 million funding round to support commercial expansion and operational scale-up.
With these preliminary MARRS data, Perfuze is preparing for FDA submission. ' This is a significant inflection point for the company, ' said Perfuze Chairperson, Hooman Hakami. ' Preliminary MARRS results support the Millipede 88 catheter's safety and effectiveness and underpin our vision to advance stroke intervention.'
About the Millipede System and MARRS Trial
Millipede 88 is a superbore aspiration catheter developed to support effective clot retrieval while maintaining navigability through challenging cerebrovascular anatomy. The MARRS trial is a prospective, multicenter, single-arm pivotal IDE study designed to evaluate the safety and effectiveness of the Millipede System in patients with large vessel occlusion stroke. Revascularization outcomes were adjudicated by an independent core laboratory.
About Perfuze
Perfuze is a privately held medical device company based in Galway, Ireland. The company is dedicated to developing advanced catheter technologies that simplify stroke procedures and aim to improve outcomes for patients suffering from acute ischemic stroke.
For more information, visit https://www.perfuze.com. Follow us on LinkedIn and X (formerly Twitter).
Disclaimer:
United States: CAUTION – Investigational device. Limited by Federal law to investigational use.
Europe: Exclusively for use in a clinical investigation.
These are preliminary results from an ongoing clinical investigation. The Clinical Study Report has not yet been approved or reviewed by regulatory authorities. Data may be subject to change and may not fully reflect the contents of the Clinical Study Report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
73% of Rural Healthcare Orgs Say They Struggle to Maintain HIPAA Compliance Due to Staffing and Funding Gaps
SAN FRANCISCO--(BUSINESS WIRE)--As cyber threats grow more frequent and sophisticated, rural hospitals and clinics face challenges on all fronts— tight budgets, limited staff, inadequate training, complex technology, and unsupportive vendors. Many are left trying to manage security tools without the IT resources to support them. 73% of rural healthcare orgs say they struggle to maintain HIPAA compliance due to staffing and funding gaps. Rural healthcare organizations are encountering more roadblocks to cybersecurity than their urban peers—and not just in one or two areas. The findings are part of a broader pattern: rural healthcare organizations are more likely to face every major cybersecurity barrier surveyed, including outdated systems, limited vendor support, and friction-filled tools that hinder care delivery. 'Small and rural hospitals are on the frontline of America's healthcare cybersecurity crisis,' said Doug Brown, founder of Black Book Research. 'The majority lack the staffing, funding, and infrastructure to defend themselves against increasingly sophisticated attacks.' Many rural health systems are operating without the tools or support to safely modernize, while continuing to serve 60 million Americans. As ransomware campaigns and phishing threats continue to rise and become more sophisticated, the tools they rely on—especially for email—are often falling short. 88% of rural leaders said they lack confidence that their current email platform is fully HIPAA compliant out of the box. 'Cyber defense is a moving target, and one that requires significant time, energy and resources,' said Kate Pierce, CIO and CISO at North Country Hospital in Vermont. Among the report's key findings: 73% of rural healthcare orgs say they struggle to maintain HIPAA compliance due to staffing and funding gaps. Rural orgs trail urban ones by 22% in adopting AI-based threat detection. 4 out of 5 rural leaders say their infrastructure can't support advanced email security. 50% say budget limitations are a top barrier to upgrading security tools—nearly double the rate of urban peers. The report also highlights a critical but often overlooked issue: what happens when security tools create friction. According to the survey, 6 out of 10 rural providers say their current secure email platform causes regular complaints and workflow delays. More than half report poor mobile usability and slow encryption that can delay care. 'We can't expect rural hospitals to meet the same compliance standards as large systems without giving them tools that fit their size and structure,' said Rick Kuawahara, Chief Compliance Officer at Paubox, 'In cybersecurity, usability is security.' When tools get in the way, staff start looking for workarounds—like reverting to personal email, skipping encryption steps, or delaying communication altogether. The report calls for secure communication tools that are built for lean teams, designed to run quietly in the background. To see the full data and recommendations, read the report: Rural Healthcare Left Vulnerable to Cyber Attacks. About Paubox
Associated Press
an hour ago
- Associated Press
Medicaid Enrollment Sees Sharp Decline; HMOs Report $1 Billion Revenue Drop
DUBLIN--(BUSINESS WIRE)--Jul 18, 2025-- The 'Minnesota Health Market Review 2025 (Part 1)' report has been added to offering. HMO profitability plunged in 2024, as HMOs and County-Based Purchasing plans reported lower revenues, higher medical expenses and large losses on operations. The number of enrollees in Medicaid managed care plans dropped by about 207,000 in 2023 and 2024, although it is still higher than before the COVID-19 pandemic. The analyst reports on these and other findings in Part One of Minnesota Health Market Review 2025. This is the 36th edition of the report, which was first published in 1990. The reports in Minnesota and five other states examine key trends and competitive strategies for health plan companies and hospital systems in those markets. Later this year, the Part Two report for Minnesota will present an analysis of the state's hospital systems and how they compete, examining 2024 Medicare cost report data on their financial results and measures of inpatient utilization. The new report finds that: Key Topics Covered: For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: MINNESOTA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HOSPITALS HEALTH HEALTH INSURANCE SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/18/2025 12:41 PM/DISC: 07/18/2025 12:41 PM
Yahoo
2 hours ago
- Yahoo
According to THE SAGE GROUP, The Current United States Prevalence of Chronic Venous Disease (CVD) Exceeds 190 Million. The Most Severe Stage, Chronic Venous Insufficiency (CVI), Afflicts Over 50 Million.
BEAUFORT, S.C., July 18, 2025--(BUSINESS WIRE)--A new report published by THE SAGE GROUP quantifies CVD prevalence and incidence for the 2020-2040 period. "Chronic venous disease afflicts 1.5 times as many people as all cardiovascular diseases combined, and five times more than those with diabetes. It is one of the most prevalent chronic diseases. However, CVD is significantly underestimated, underdiagnosed and undertreated," stated Mary L. Yost, President. CVD represents a spectrum of medical conditions involving morphological and functional abnormalities of the venous system. Severity ranges from mild disease such as spider veins, reticular veins and telangiectasia to active venous ulcers. The most severe stage of CVD, chronic venous insufficiency (CVI), is characterized by edema, skin changes and ulcers. Commenting on CVI, Yost observed, "The primary causes are damaged or incompetent 'refluxing' valves and obstructions due to deep vein thrombosis (DVT). CVI is strongly associated with cardiovascular disease sharing many risk factors. CVI increases the risk of all-cause mortality by 3X." "If untreated, CVI progresses to more severe disease, including venous ulcers. In 2025, over 2 million individuals suffer from venous ulcers generating direct medical costs of $55 to $70 billion," Yost continued. "Our venous disease estimates are higher than most of the commonly quoted numbers," Yost stated. "Our review of the literature concluded that many of the frequently quoted, older studies have significant limitations. This is especially true for venous ulcers with widely varying incidence and prevalence estimates. Venous ulcers are frequently underestimated because approximately half of patients self-treat." About the Report: Chronic Venous Disease (CVD) Epidemiology, Prevalence, Incidence and Progression The report focuses on CVD epidemiology, prevalence, incidence and the percent progression to more severe disease. The primary purpose of this research is to estimate the number of U.S. adults with CVD, the number with CVI and the number in each of the C1-C6 CEAP classes. Patient prevalence and incidence estimates for the 2020-2040 period are provided in 5-year increments. Additional information: THE SAGE GROUP, a research and consulting company, specializes in arterial and venous disease in the lower limbs. Additional information: View source version on Contacts THE SAGE GROUP, Beaufort SCMary Yost, (404) 520-6652yost@ Sign in to access your portfolio
